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Abstract
Purpose:  Botulinum  toxin  (BT)  injection  is  a  new  treatment  for  piriformis  syndrome  (PS).  The
main purpose  of  our  study  was  to  use  MRI  to  evaluate  changes  in  piriformis  muscle  morphology
after treatment  with  BT  injections.
Patients  and  methods:  Twenty  patients  presenting  with  PS  who  had  undergone  an  MRI  were
included retrospectively:  12  patients  treated  with  BT  injections  and  eight  untreated  patients.
The following  parameters  were  assessed  and  compared  to  a  normal  contralateral  muscle:  maxi-
mum thickness,  volume,  and  Goutallier’s  classiﬁcation  grade  of  fatty  inﬁltration  of  the  piriformis
and internal  obturator  muscles.  Pain  was  assessed  through  a  visual  analogue  scale  (VAS).
Results: The  untreated  patients  had  no  signiﬁcant  difference  in  the  volume  (P  =  1.0)  or  thick-
ness of  the  piriformis  muscle  (P  =  0.61).  The  treated  patients  showed  a  signiﬁcant  reduction  in
3the thickness  (−4.2  mm;  P  <  0.001)  and  volume  (−74.4  mm ;  P  <  0.001)  and  an  increase  in  the
fatty inﬁltration  (P  <  0.001)  of  the  piriformis  muscle  treated  by  BT  injection.  Muscular  atrophy
∗ Corresponding author.
E-mail address: saubry@chu-besancon.fr (S. Aubry).
2211-5684/$ — see front matter © 2014 Éditions franc¸aises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
http://dx.doi.org/10.1016/j.diii.2014.02.015
38  M.  Al-Al-Shaikh  et  al.
was  correlated  with  the  number  of  BT  injections  and  with  the  time  until  an  MRI  was  performed.
There was  also  signiﬁcant  pain  relief  after  BT  treatment.
Conclusion:  BT  leads  to  atrophy  and  fatty  degeneration  of  the  piriformis  muscle  that  can  be
quantiﬁed by  MRI  and  these  factors  explain  why  BT  injections  are  effective  in  the  treatment  of
PS.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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tometimes  buttock  pain  or  pain  beginning  in  the  buttocks
nd  radiating  to  the  lower  limb  can  originate  in  the  piri-
ormis  muscle.  This  may  be  due  to  a  problem  in  the  muscle
tself  or  to  a  permanent  or  intermittent  compression  of  the
runk  of  the  sciatic  nerve  (or  ischiatic  nerve)  as  it  passes  the
iriformis  muscle  [1].
In  terms  of  anatomy,  the  piriformis  muscles  have  a
riangular  muscular  body,  with  the  base  of  each  muscle
nserted  into  each  side  of  the  ventral  surface  of  the  sacrum
round  the  2nd  and  3rd  sacral  foramina.  The  piriformis
uscle  exits  the  pelvic  cavity  by  sliding  through  the  greater
ciatic  notch  of  the  os  coxae,  above  the  sacrospinous
igament.  It  then  crosses  the  gluteal  region  diagonally
eading  downwards  to  terminate  at  the  superior  border  of
he  greater  trochanter  of  the  femur  (Fig.  1).  In  the  gluteal
egion,  it  is  situated  under  the  gluteus  maximus  muscle
nd  above  the  termination  of  the  obturator  internus  muscle
nd  the  gemellus  muscles.  This  means  that  the  piriformis
uscle  forms  the  border  between  two  zones  that  muscles
igure 1. Posterior view of the right gluteal region. The sciatic
erve (arrow) passes through the infrapiriform foramen, bordered
uperiorly by the piriformis muscle (white arrow), and inferiorly
y the portion of the obturator internus muscle that is outside the
elvis (white arrowhead).
t
o
o
o
f
a
i
i
i
o
w
[
t
n
a
t
t
a
r
P
T
r
w
D
A
i
i
s
r
tnd  ligaments  pass  through,  known  as  the  suprapiriform
oramen  and  infrapiriform  foramen.  The  superior  gluteal
essels  and  nerves  pass  through  the  suprapiriform  fora-
en.  The  sciatic  nerve  courses  through  the  infrapiriform
oramen,  together  with  the  inferior  gluteal  and  pudendal
erves.  There  are  anatomical  variations  in  the  course  of
he  sciatic  nerve  through  the  infrapiriform  foramen.  These
onsist  in  particular  of  the  muscle  being  penetrated  by  the
ibial  or  common  ﬁbular  nerves  that  form  the  sciatic  nerve
11.7%).  The  tibial  nerve  can  also  pass  above  the  piriformis
uscle,  through  the  suprapiriform  foramen,  while  the
ommon  ﬁbular  nerve  courses  through  the  infrapiriform
oramen  (3.3%)  [2].  More  rarely,  the  undivided  sciatic  nerve
an  penetrate  the  piriformis  muscle  (0.8%)  [2,3].
Piriformis  syndrome  (PS)  is  sciatica  that  begins  in  the  but-
ocks,  or  buttock  pain  that  is  secondary  to  compression  of
he  sciatic  nerve  as  it  passes  between  the  piriformis  and
bturator  internus  muscles.  It  poses  problems  both  in  terms
f  treatment  and  diagnosis,  given  that  there  is  an  absence
f  clinical  or  other  signs  that  are  pathognomonic.  Chronic
orms  can  be  treated  with  botulinum  toxin  (BT)  injections,
nd  this  is  usually  done  with  sonography  guiding  in  the  pir-
formis  muscle  or  under  CT  guidance  into  the  obturator
nternus  muscle.  Currently,  the  effect  that  botulinum  toxin
njections  have  on  the  muscle  is  poorly  understood,  and  to
ur  knowledge  there  is  only  one  team  that  has  published
ork  using  MRI  to  assess  the  muscle  changes  triggered  by  BT
4,5].  The  main  objective  of  this  study  is  therefore  to  assess
he  effect  of  BT  injections  on  the  piriformis  muscle  (thick-
ess,  fatty  degeneration,  volume).  The  secondary  objectives
re  to  study  the  impact  of  the  number  of  injections  and  the
ime  from  starting  treatment  to  an  MRI  being  carried  out  on
he  morphological  parameters  of  muscles  treated  with  BT,
nd  to  assess  the  efﬁcacy  of  the  treatment  in  terms  of  pain
elief.
atients and methods
his  was  a  single-centre  case-control  study  that  did  not
equire  endorsement  from  an  ethics  committee  because  it
as  retrospective.
eﬁnition of the disorder and recruitment
ll  of  the  subjects  consulted  a  hospital  doctor  specialising
n  physical,  sports,  and  rehabilitation  medicine.  During  the
nterview,  patients  sometimes  described  pain  on  climbing
tairs  or  walking  uphill.  There  was  often  increased  pain  on
est.  Buttock  pain  was  felt,  radiating  through  the  thigh  along
he  course  of  the  sciatic  nerve,  but  not  below  the  knee,
nd  piriformis  syndrome  39
Figure 3. Cross-section from CT guidance during botulinum toxin
(BT) injection into the portion of the obturator internus muscle that
is outside the pelvis (arrow). Two needles are placed in the muscle,
passing each side of the sciatic nerve (arrowhead). CT guidance
was chosen over sonography because the obturator internus muscle
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pMRI  evaluation  of  changes  in  piriformis  muscle  morphology  a
mimicking  sciatica  due  to  disc  herniation  at  the  S1  nerve
root  [1].  In  order  to  prove  that  these  pains  had  a  local  mus-
cular  origin,  a  number  of  diagnostic  manoeuvres  were  used
including  Freiberg’s  manoeuvre,  Pace’s  manoeuvre  [6],  and
the  heel-contralateral  knee  manoeuvre  [3].
A  diagnosis  of  PS  was  made  based  on  the  association  of
the  clinical  arguments  and  signs  on  electroneuromyography
(ENMG).  The  purpose  of  ENMG  is  to  detect  whether  there
is  L5  or  S1  nerve  root  involvement  and  to  exclude  nerve
trunk  involvement.  In  general,  neither  acute  nor  chronic
neurogenic  signs  are  found  in  PS.  By  contrast  a  nerve  conduc-
tion  study  using  the  ﬂexion—adduction—internal  rotation
manoeuvre  [7]  looks  at  the  affected  side  for  a  delay  in  the
conduction  of  the  H  reﬂex  compared  to  a  reference  point
with  a  threshold  estimated  at  1.8  ms  [8].  Laboratory  stud-
ies  can  be  requested  in  order  to  exclude  an  inﬂammatory
syndrome.  Imaging  studies  (standard  radiography,  CT,  MRI)
of  the  spine,  hips,  and  pelvis  can  exclude  the  differential
diagnoses  of  PS  and  look  for  an  extrinsic  compression  of  the
sciatic  nerve.  Recruitment  was  carried  out  retrospectively
among  all  patients  who  had  undergone  MRI  as  part  of  investi-
gations  for  PS  between  10/12/2009  and  28/06/2012,  a  total
of  23  subjects.
Inclusion and exclusion criteria
Criteria  for  inclusion  and  exclusion  from  the  ‘‘treatment’’
group:  We  included  patients  who  presented  PS  and  had
received  BT  injections  in  the  piriformis  muscle  under  sono-
graphic  guidance  (Fig.  2)  or  under  CT  guidance  into  the
piriformis  and  obturator  internus  muscles  (Fig.  3).  The  doses
injected  were  100  IU  of  BT  (Botox®)  in  one  muscle.  Patients
who  had  been  treated  with  surgical  release  of  the  piriformis
muscle  were  excluded.
Inclusion  criteria  for  the  ‘‘control’’  group:  patients  pre-
senting  PS  who  had  received  neither  treatment  with  BT
injection  nor  surgical  treatment.Variables studied
In  the  treated  patients,  the  number  of  botulinum  toxin  injec-
tions  and  the  time  between  starting  treatment  with  BT
Figure 2. Sonographic cross-section taken during botulinum toxin
(BT) injection into the piriformis muscle. P: piriformis muscle; S:
sacrum.
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f the sciatic nerve.
nd  an  MRI  being  performed  were  documented.  Pain  was
ssessed  using  a  visual  analogue  scale  (VAS),  with  buttock
ain  (VASFess)  and  sciatic  pain  (VASSciat)  routinely  rated  on
he  day  of  the  MRI  scan.
All  subjects  had  1.5  or  3  T  MRI  examinations  (MRI  1.5  T
rea  Siemens,  Erlangen,  Germany  and  MRI  3  T  HDX  Signa
xcite  General  Electric  Medical  System,  USA).  The  protocol
as  as  follows:  pelvic  MRI  with  spin  echo  T1-weighted  acqui-
ition  of  axial  cross-sections  (thickness:  5  mm,  TE:  20  ms
nd  TR:  860  ms),  proton  density-weighted  fat-saturated  (PD
atSat)  axial  and  coronal  cross-sections  (thickness:  5  mm,
E:  13—35  ms  and  TR:  2200—2800  ms).  The  MRI  studies  were
arried  out  on  consoles  equipped  with  the  software  Osirix
V  3.9.1  64  bit),  which  allowed  for  an  assessment  of  the
iriformis  and  obturator  internus  muscles  in  terms  of  the
ollowing  criteria:
quantitative  values:
◦ measure  of  the  maximum  transverse  thickness  in  mmof  the  piriformis  (TPir)  and  obturator  internus  (TObt)
muscles  (Fig.  4),
igure 4. Axial T1-weighted cross-section. Thickness of the pir-
formis muscles measured in a 59-year old female treated with BT
njection to the left piriformis muscle. Amyotrophy of the left piri-
ormis (10.8-mm thick) compared to the right side (17.1-mm thick).
4 M.  Al-Al-Shaikh  et  al.
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◦ calculation  of  the  volume  of  the  piriformis  (VPir)  and
obturator  internus  (VObt)  muscles  and  of  the  portion
of  the  obturator  internus  outside  the  pelvis  (VObtExo):
segmentation  was  performed  by  manually  delineating
the  contours  of  each  anatomical  structure  of  muscle
sequentially  cross-section  by  cross-section  using  the
tool  ‘‘ROI  of  closed  polygon’’  then  the  volume  was  cal-
culated  in  mm3 using  ‘‘computed  volume’’  (Fig.  5);
qualitative  values:
◦ assessment  of  the  fatty  inﬁltration  of  the  piri-
formis  (FIPir)  and  obturator  internus  (FIObt)  muscles.
Fatty  inﬁltration  was  assessed  using  the  ﬁve-grade
Goutallier’s  classiﬁcation  [9]:  grade  0  =  no  fat,  grade
1  =  streaks  of  fat,  grade  2  =  more  muscle  than  fat,  grade
3  =  equal  muscle  and  fat,  grade  4  =  more  fat  than  muscle
(Fig.  6),
◦ looking  for  signs  of  acute  denervation  in  the  form  of
high-signal  intensity  within  the  muscles  on  FatSat  PD-
weighted  images.
tatistical analysis
he  statistical  analyses  were  carried  out  using  the  software
AS  for  Windows  (v9.3,  SAS  Institute  Inc.,  Cary  NC,  USA).
he  mean  (M)  and  standard  deviation  (SD)  of  the  quantita-
ive  and  qualitative  values  were  calculated.  For  all  tests,
-values  below  0.05  were  considered  to  be  statistically  sig-
iﬁcant.  In  the  ‘‘treatment’’  and  ‘‘control’’  populations  the
ifferences  between  the  healthy  and  pathological  side  in
erms  of  quantitative  variables  (TPir,  TObt,  VPir,  VObt,  VOb-
Exo)  were  analysed  using  the  paired  Wilcoxon  signed-rank
est,  and  the  differences  in  terms  of  qualitative  variables
FIPir,  FIObt)  were  analysed  using  the  Kruskal-Wallis  test.
he  correlation  between  the  parameters  of  muscle  morphol-
gy  (thickness,  volume,  fatty  inﬁltration)  and  the  number  of
otox® injections  on  the  one  hand  and  the  time  to  an  MRI
eing  carried  out  on  the  other  were  studied  by  calculat-
ng  Spearman’s  correlation  coefﬁcient  (R).  When  there  was
 statistically  signiﬁcant  correlation  (P  <  0.05),  we  used  the
ollowing  convention:
0 <  |R|  < 0.4:  weak  correlation;
0.4  <  |R|  <  0.7:  moderate  correlation;
0.7  <  |R|  <  1:  strong  correlation.
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igure 5. Manual segmentation of the right piriformis muscle on an ax
he segmented piriformis muscle (anterior view) (b).igure 6. Grade 3 Goutallier’s classiﬁcation of fatty inﬁltration
f the right piriformis muscle in a 42-year old patient treated with
T in the right piriformis muscle.
The  differences  in  buttock  pain  and  sciatic  pain  before
nd  after  treatment  in  the  ‘‘treatment’’  population  were
nalysed  using  the  Wilcoxon  signed-rank  test.
esults
escription of the included population
mong  the  population  of  23  subjects,  three  patients  who
ad  received  surgical  treatment  were  excluded.  The  treated
ubjects  (n  =  12)  had  a  mean  age  of  46.5  years  (min  26
ears—max  63  years)  and  there  was  a  strong  preponder-
nce  of  females  (sex  ratio:  2/10).  Ten  subjects  had  received
T  injections  in  the  piriformis  muscle  only,  and  two  had
eceived  BT  injections  in  the  piriformis  and  obturator  inter-
us  muscles.  The  time  between  starting  treatment  with  BT
nd  an  MRI  being  performed  was  a  mean  of  7.3  months
SD  =  5.2).  Patients  received  1—4  injections  of  BT  (M  =  2.1;
D  =  1.1).  The  control  group  was  made  up  of  eight  subjects
ith  a  mean  age  of  48  years  (min  24  years—max  77  years)
nd  once  again  there  was  a  clear  preponderance  of  females
sex  ratio:  2/6).esults from the ‘‘control’’ population
ased  on  the  signed-rank  paired  test,  there  was  no  statisti-
ally  signiﬁcant  difference  in  the  variables  VObt  (P  =  0.054),
ial T1-weighted cross-section (a) then 3D volume rendered view of
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pMRI  evaluation  of  changes  in  piriformis  muscle  morphology  a
TObt  (P  =  0.06),  VPir  (P  =  1.0),  TPir  (P  =  0.61)  or  VObtExo
(P  =  0.97).  This  means  that  the  mean  of  each  of  these
variables  is  the  same  whether  from  the  healthy  side  or
pathological  side  in  untreated  patients.
Based  on  the  Kruskal-Wallis  test,  we  noted  that  there  was
no  statistically  signiﬁcant  difference  in  the  grading  of  FIPir
(P  =  0.73)  or  FIObt  (P  =  0.91)  between  the  pathological  and
healthy  sides  in  untreated  patients.
Results from the ‘‘treatment’’ population
Based  on  the  signed-rank  paired  test,  there  was  a  sta-
tistically  signiﬁcant  difference  in  VPir  (P  <  0.001)  and  TPir
(P  <  0.001)  while  the  other  values  (VObt,  VObtExo  and  TObt)
did  not  show  a  signiﬁcant  difference.  For  example,  VPir  was
1.4  times  greater  on  the  healthy  side  than  on  the  patholog-
ical  side  in  treated  patients  (Table  1).
Based  on  the  Kruskal-Wallis  test,  we  noted  that  there  was
a  statistically  signiﬁcant  difference  in  the  grading  of  FIPir
(P  =  0.0002)  and  FIObt  (P  =  0.023)  between  the  pathological
and  healthy  sides  in  treated  patients.
Patients  received  a  mean  of  2.1  BT  injections  (min  =  1,
max  =  4,  SD  =  1.11).  We  noted  a  strong  correlation  between
TPir  and  the  number  of  BT  injections  (R  =  −0.77,  P  <  0.001):
as  the  number  of  BT  injections  increases,  piriformis  mus-
cle  thickness  falls.  We  saw  a  moderate  correlation  between
the  number  of  BT  injections  and  the  fall  in  piriformis  mus-
cle  volume  (R  =  −0.55,  P  =  0.003).  As  the  number  of  BT
injections  increases,  the  grading  of  the  degree  of  fatty
inﬁltration  of  the  piriformis  muscle  increases  (R  =  0.69,
P  <  0.001).
The  MRI  scans  were  carried  out  a  mean  of  6.1  months
after  BT  treatment  was  started.  We  noted  a  strong  correla-
tion  between  the  length  of  time  until  an  MRI  was  performed
and  a  fall  in  TPir  (R  =  −0.69,  P  <  0.001)  while  there  was  a  sig-
niﬁcant  but  weak  correlation  between  this  timescale  and  a
fall  in  VPir  (R  =  −0.39,  P  =  0.04).
No  treated  patient  presented  any  signs  of  acute  dener-
vation  on  the  PD-FS  sequence.
The  subgroup  of  patients  who  received  injections  in  the
obturator  internus  muscle  is  too  small  (n  =  2)  to  be  consid-
ered  individually  for  statistical  analysis.  We  noted  that  on
the  treated  side  in  these  two  patients,  there  was  a  mean
TObt  reduction  of  2.4  mm,  mean  VObt  fall  of  30.7  mm3,
and  mean  VObtExo  reduction  of  32.3  mm3,  and  both  cases
developed  grade  1  fatty  degeneration  of  the  obturator
internus.
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Table  1  Thickness  (mm),  volume  (mm3)  and  comparative  tes
healthy  side  versus  the  pathological  side  in  treated  patients.  T
Variables n Healthy  side  Pathologica
Mean  Standard
deviation
Mean  S
d
VPir  (mm3)  12  254.08  60.90  179.66  5
TPir  (mm)  12  16.21  1.61  11.99  2
VObt  (mm3)  12  333.14  80.47  329.98  6
VObtExo  (mm3)  12  112.16  146.79  57.48  2
TObt  (mm)  12  10.97  1.65  9.80  1iriformis  syndrome  41
ssessment of pain relief
here  was  a  very  signiﬁcant  difference  (P  <  0.001)  on  VAS
cores  between  buttock  pain  before  (VAS  =  7.50  ±  1.61)
nd  after  treatment  (VAS  = 3.20  ±  1.47),  and  between  sci-
tic  pain  before  (VAS  =  7.04  ±  1.05)  and  after  treatment
VAS  =  1.7  ±  1.76).
iscussion
iriformis  syndrome  is  deﬁned  as  the  compression  of  the  sci-
tic  nerve  within  the  infrapiriform  foramen  [10]. The  ﬁrst
escription  was  made  by  Yeoman  in  1928  but  the  credit  for
aking  this  pure  nerve  compression  syndrome  into  a  true
isease  entity,  and  for  naming  it,  goes  to  Robinson  in  1947
11]. Although  it  has  been  discussed  for  a  long  time,  it  is  cur-
ently  recognised  as  a  genuine  compression  neuropathy  due
o  clinical,  anatomical,  and  electrical  studies  and  because
f  the  progress  in  modern  imaging.  Over  the  last  few  years
here  has  been  an  increase  in  publications,  especially  in
erms  of  information  from  MRI  and  regarding  non-surgical
reatment  options  [10].  This  is  one  of  the  rare  causes  of  sci-
tic  pain  that  is  not  spinal  in  origin  [12]. Although  it  has
een  established  as  a genuine  compression  neuropathy  orig-
nating  from  the  passage  of  the  sciatic  nerve  through  the
nfrapiriform  foramen,  there  are  various  potential  aetiolo-
ies  for  this  compression.  It  may  be  due  to  inﬂammation,
rauma,  a  tumour,  a  malformation  [13,14], but  most  often  it
s  muscular,  and  it  is  this  latter  aetiology  that  we  addressed.
here  are  a  few  studies  that  have  shown  that  the  obturator
nternus  muscle  may  also  potentially  compress  the  sciatic
erve  within  the  pelvis  [2,3,15].  Since  it  forms  the  medial
order  of  the  infrapiriform  foramen,  a  potential  site  of
ompression,  entrapment  between  the  piriformis  and  obtu-
ator  internus  muscles  could  be  suspected  [2,3].
MRI  sometimes  demonstrates  hypertrophy  of  the  pir-
formis  muscle  [16,17],  an  anatomical  variation  of  the
iriformis  muscle  or  the  course  of  the  sciatic  nerve  [18—20],
r  a  change  in  the  sciatic  nerve  signal,  and  these  changes
ffect  their  respective  anatomical  relationships  with  adja-
ent  structures.  One  study  showed  that  asymmetry  of  the
iriformis  muscles  combined  with  a  sciatic  nerve  signal
bnormality  had  a  speciﬁcity  of  93%  and  sensitivity  of  64%
or  predicting  a  good  outcome  to  surgery  on  the  piriformis
uscle  [21],  but,  in  these  surgically  treated  patients,  38.5%
resented  hypertrophy  and  15%  atrophy  of  the  piriformis.
t  of  the  obturator  internus  and  piriformis  muscles  on  the
he  P-values  (<0.05)  are  in  bold  print.
l  side Mean  of  the
differences
(pathological—healthy)
Paired
signed-rank  test
Ptandard
eviation
4.76  −74.42  <0.001
.15  −4.22  <0.001
9.73  −3.15  0.81
7.18  −54.68  0.22
.52  −1.17  0.091
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whose  symptoms  are  treatment-resistant  in  order  to  check
what  effect  BT  has  had  on  the  treated  muscle,  and  to  assess2  
n  addition,  Russell  et  al.  [22]  used  a  population  of  100
symptomatic  subjects  (200  buttocks)  to  demonstrate  that
0%  of  cases  showed  asymmetry  in  piriformis  muscle  thick-
ess  ranging  from  3  to  8  mm.  Moreover,  there  are  true  cases
f  PS  in  which  the  piriformis  is  of  normal  size  [23]. In  our
‘control’’  population,  the  absence  of  signiﬁcant  asymmetry
n  piriformis  muscle  thickness  and  volume  argues  in  favour
f  this  being  a  nerve  compression  that  is  perhaps  not  simply
ue  to  hypertrophy  of  the  piriformis,  which  is  not  always
resent  and  has  not  been  formally  demonstrated,  but  one
hat  is  instead  a  functional  compression  of  the  sciatic  nerve
uring  muscle  contraction.  This  absence  of  hypertrophy  of
he  piriformis  muscle  could  also  be  related  to  the  very  small
ample  size  (n  =  8).  A  role  for  the  obturator  internus  muscle
n  PS  has  also  been  suggested  [2].  Meknas  et  al.  published
 case  series  of  six  patients  whose  symptoms  were  relieved
y  surgical  release  of  the  obturator  internus  muscle  [15],
hich  led  us  to  also  inject  this  muscle  in  two  patients,  but
he  value  of  treating  this  site  needs  to  be  studied  in  larger
opulations.
The  current  chronological  treatment  plan  for  PS  is
ased  on  ﬁrstly  introducing  analgesia  (non-opioids  and
eak  opioids)  and  muscle  relaxants  combined  with  struc-
ured  physiotherapy,  and  if  this  management  is  ineffective
r  insufﬁcient,  there  is  recourse  to  intramuscular  injec-
ions  of  botulinum  toxin  in  the  affected  piriformis  muscle
3,4,24—26].  Surgery  to  release  the  distal  tendon  is  dis-
ussed  in  a  few  treatment-resistant  cases.
Intramuscular  botulinum  toxin  injections  are  used  to
educe  muscle  overactivity,  especially  in  the  treatment  of
ocal  spasticity.  Botulinum  toxin  blocks  pre-synaptic  conduc-
ion  thus  inhibiting  cholinergic  mediation  and  preventing
he  injected  muscle  from  contracting,  resulting  in  paresis
f  this  muscle.  The  injection  must  be  as  close  as  possible
o  the  motor  end-plate.  This  leads  to  a  beneﬁcial  effect  on
iriformis  muscle  contracture  and  it  indirectly  relieves  sci-
tic  pain.  The  clinical  results  from  publications  discussing
se  of  BT  seem  to  be  very  encouraging:  Calvillo  et  al.  [27]
sed  50  IU  (12  good  outcomes  out  of  14),  Childers  et  al.
25]  used  100  IU  (excellent  and  very  good  outcomes  in  nine
lacebo-controlled  cases),  Yoon  et  al.  [28]  used  150  IU  in  20
atients,  and  Michel  et  al.  [3]  used  50—100  IU  in  250  patients
hose  results  assessed  by  VAS  were  good  and  very  good  in
4  cases  (77  %),  moderate  in  eight  cases  (7.4  %)  and  poor
n  19  cases  (15.6  %).  In  our  series,  the  efﬁcacy  of  BT  also
ranslated  into  a  very  signiﬁcant  fall  in  VAS  ratings  post-
njection  (P  <  0.001):  we  noted  a  reduction  in  buttock  pain
f  around  50%  after  treatment,  and  a  75%  fall  in  sciatic  pain.
ur  results  are  therefore  in  agreement  with  data  from  the
iterature  and  together  conﬁrm  the  efﬁcacy  of  botulinum
oxin  injection  in  PS  [3,25,26];  these  works,  however,  have
ocused  purely  on  a  clinical  assessment  of  efﬁcacy  and  only
 single  team  to  date  has  attempted  to  link  this  efﬁcacy  to
hanges  in  muscle  morphology  [4,5].  Our  study  shows  that  BT
auses  atrophy  and  fatty  inﬁltration  of  the  piriformis  mus-
le.  These  results  are  in  agreement  with  those  from  the  nine
atients  assessed  by  MRI  by  Fanucci  et  al.  [4,5],  and  they
rove  that:
use  of  sonographic  and  electroneuromyographic  land-
marks  meant  that  the  BT  injections  in  the  piriformis  were
performed  correctly;
t
tM.  Al-Al-Shaikh  et  al.
BT  does  indeed  cause  atrophy  and  fatty  inﬁltration  of  the
piriformis  muscle  secondary  to  muscular  denervation.
The  patients  in  our  ‘‘treatment’’  population  underwent
RI  a  mean  of  6.1  months  after  they  started  BT  treatment:
his  was  for  medium  term  follow-up,  which  explains  why
one  of  the  patients  presented  any  sign  of  acute  denerva-
ion  on  the  PD-weighted  FatSat  sequence.  The  phenomena
f  atrophy  and  fatty  inﬁltration  observed  were  relatively
elayed  and  they  correlated  both  with  the  number  of  BT
njections  and  the  timescale  between  the  start  of  treatment
nd  the  MRI.  Since  the  duration  of  action  of  BT  is  3—5  months
nd  the  effect  seems  to  be  cumulative,  in  practice  this
rompts  a  repeat  BT  injection  from  the  third  month  if  painful
ymptoms  recur  or  there  is  insufﬁcient  improvement:  our
atients  received  a  mean  of  2.1  BT  injections.  There  is  also
 recommendation  that  the  timescale  of  a  minimum  of  three
onths  between  two  injections  should  be  respected  in  order
o  avoid  sensitisation  phenomena  (allergy).  Using  this  treat-
ent  plan,  it  seems  that  there  is  a  place  for  follow-up  MRI
cans  in  patients  whose  symptoms  are  treatment-resistant
n  order  to  check  what  effect  the  BT  has  had  on  the  muscle,
nd  to  assess  muscle  mass  in  view  of  potential  additional
njections.
The  three  surgical  cases  that  were  excluded  from  the
eries  also  presented  atrophy  (muscle  volume  fell  by  almost
alf:  228  mm3 on  the  operated  side  as  against  402.4  mm3
n  the  healthy  side)  and  fatty  inﬁltration  of  the  piriformis
uscle  (one  case  of  grade  2  fatty  inﬁltration,  and  two  grade
 cases),  which  can  easily  be  understood  because  the  muscle
ad  been  released.  This  treatment  remains  a  last  resort,  on
he  condition  that  medical  treatment  has  been  tried  and  has
ailed,  and  that  the  diagnosis  of  PS  is  absolutely  certain.
he  primary  objective  is  to  release  the  piriformis  muscle
y  performing  a  tenotomy  at  its  insertion  on  the  greater
rochanter.
The  main  forms  of  bias  and  the  drawbacks  to  our  study
re:  the  possibility  of  selection  bias  that  is  inherent  in  the
etrospective  design  of  the  study,  and  the  sample  size  being
oo  small  to  carry  out  a multivariate  analysis.  A  further
ongitudinal  analysis  is  needed  in  order  to  evaluate  clinical
fﬁcacy  in  the  longer  term  and  to  make  a  better  assessment
f  the  postulated  link  between  changes  in  muscle  morphol-
gy  and  clinical  efﬁcacy.
onclusion
elvic  MRI  is  currently  the  best  examination  for  exploring
he  local  anatomy,  including  the  bone  and  muscle  borders
f  the  infrapiriform  foramen,  and  for  visualising  the  course
f  the  sciatic  nerve.  Most  importantly  it  allows  for  a  quan-
itative  assessment  of  changes  in  muscle  morphology.  Our
tudy  made  a  link  between  the  efﬁcacy  of  BT  in  the  pir-
formis  muscle  for  the  treatment  of  PS  and  the  atrophy
nd  fatty  inﬁltration  that  it  triggers.  This  means  that  there
eems  to  be  a  place  for  follow-up  MRI  scans  in  patientshe  remaining  muscle  mass  with  a  view  to  additional  injec-
ions.
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